ImmunoACT announces the approval of India's first CAR-T cell therapy 'NexCAR19'
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
Subscribe To Our Newsletter & Stay Updated